Total Eclipse 91 Posted September 10 First-line pharmacological treatments for anxiety disorders include antidepressants. Unfortunately, treatment response rates to these standard agents are less than optimal, with 40–60% of patients continuing to have residual, impairing symptoms. Although there have been no studies evaluating the effects of cannabis or cannabidiol (CBD - the component thought to be most anxiety-relieving) in clinical populations, a recent survey of 2032 medical cannabis users, found that 44% (n=888) reported using cannabis for anxiety, suggesting further research on the anxiolytic effects of cannabis is required. The objective of this study is to provide systematic, prospectively derived data on the effects of CBD and THC in anxiety disorders. At the end of the study, participants will enter follow-up care with the study doctor. Organization McMaster University Medical Centre Principal Investigator Michael Van Ameringen, MD Eligibility Criteria Participants must have a primary diagnosis of an anxiety disorder. Eligible participants are between 21-65 years of age, as there is a growing body of scientific evidence that smoked cannabis may have deleterious effects on the developing brain. Patients cannot have a lifetime history of cannabis use disorder or daily cannabis use. Contact The MacAnxiety Research Centre, 905-921-7644 or e-mail macanxietyresearch@gmail.comor check out our website at macanxiety.com Location Hamilton, ON State ON Study End Date September 30, 2024 Quote Share this post Link to post Share on other sites